PharmStars’ Eighth Cohort to Focus on 'Digital Innovations in Rare Disease' and Include Funding for Startups

January 03, 2025 12:00 AM AEDT | By EIN Presswire
 PharmStars’ Eighth Cohort to Focus on 'Digital Innovations in Rare Disease' and Include Funding for Startups
Image source: EIN Presswire

PharmStars is accepting applications for its eighth cohort: “Digital Innovations in Rare Disease.” Startups will receive funding. Apply by January 26. BOSTON, MA, UNITED STATES, January 2, 2025 /EINPresswire.com/ -- PharmStars, the pharma-focused accelerator for digital health startups, is now accepting applications for its eighth cohort, which will take place in Spring 2025 around the theme “Digital Innovations in Rare Disease.” Startups with a digital product or prototype in this theme area should apply by January 26, 2025. Startups graduating from this cohort will receive investment funding from the PharmStars Ventures Fund.

PharmStars’ Spring 2025 accelerator program is open to startups with digital health solutions that the biopharma industry can use to improve all aspects of rare disease drug development, treatment, and care. Startups with digital health innovations in patient identification and diagnosis, clinical trial design and execution, and patient care for any rare disease are invited to apply by the deadline.

Beginning in 2025, upon completion of the accelerator, startups will receive investment funding. Graduating startups will receive a $150,000 investment from the PharmStars Ventures Fund.

PharmStars is committed to bridging the “pharma-startup gap.” The accelerator's mission is to help biopharma and digital health startups overcome cultural and other barriers to partnership, accelerating the adoption of digital innovations to improve patient outcomes. PharmaU, PharmStars’ signature education and mentoring program, equips participating startups to effectively engage with pharma companies as clients and partners.

The PharmStars accelerator program is transformative for startups. Scott McQuiggan, co-founder and CEO of Social Cascade and a Fall 2024 accelerator graduate, remarked, “PharmaU is the premier crash course in the pharma industry. It taught me more in 10 weeks than any program I have ever been a part of.”

Each PharmStars cohort theme is selected by PharmStars’ pharma members because of their strong interest in it. The Spring 2025 cohort will comprise startups with digital innovations related to any rare disease. “People with a rare disease often face significant challenges, including limited awareness, delayed diagnosis, and insufficient therapies,” said Naomi Fried, PharmStars’ founder and CEO. “Our pharma members are eager to embrace digital innovations being developed by startups to address these and other issues in rare disease.”

PharmStars’ pharma members will have priority access to the startups that complete the accelerator program. The program will culminate with a private Showcase Event in Boston in May 2025, at which each startup will present to and meet one-on-one with PharmStars’ pharma members.

The Spring 2025 program will be PharmStars’ eighth cohort. Since it launched in June 2021, 79 digital health startups have successfully graduated from the program.

Starting this Spring, a new benefit for participating startups is that they will receive an investment from the PharmStars Ventures Fund when they graduate. Naomi Fried shared, “PharmStars propels the growth of its startups by offering a rigorous education in the pharma industry, exceptional personalized mentoring from former pharma executives, and unmatched access to pharma decision-makers. We’re thrilled to now extend our support of our startups to include funding.”

Applications for the Spring 2025 accelerator program, along with additional details, are now available on the PharmStars website. PharmStars is also accepting a limited number of additional pharma and biotech members for 2025. Membership information can also be found at www.PharmStars.com.

About PharmStars

PharmStars is the only member-based, pharma-focused accelerator for digital health startups. Through our extensive expertise across pharma, startups, digital health, and innovation, we understand the challenges that pharma and startups face when seeking to collaborate. Our PharmaU program supports digital health startups and our pharma members in “bridging the pharma-startup gap,” leading to greater success and faster adoption of “beyond the molecule” solutions for patients. More information at www.PharmStars.com.

PharmStars
www.PharmStars.com
+1 617-333-8723
[email protected]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.